Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial

Cited by (641)

Items 401–500 of 641

1. Screening and evaluation of purines-degrading lactic acid bacteria isolated from traditional fermented foods in Yunnan Province and their uric acid-lowering effects in vivo
   Zhen Liu, Xing-Yuan Zou, Yue Jiang, Shan Li, Xia Ou, Chuang Huang, Chen‐Jian Liu, Xiaoran Li · 2025 · Frontiers in Microbiology
2. Hyperuricemia, gout and high cardiovascular risk - how to manage them in clinical practice
   Victor V. Fomin, T E Morosova, Vladimir Viktorovich Tsurko · 2019 · Terapevticheskii arkhiv
3. Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease
   Hsin Hsiang Huang, Yun‐Yi Chen, Yu‐Wei Fang, Hung‐Hsiang Liou, Jingtong Wang, Ming-Hsein Tsai · 2024 · Medical Science Monitor
4. Managing Gout in Patients with Metabolic Syndrome
   Esther Ebstein, Sébastien Ottaviani · 2024 · Drugs & Aging
5. How to manage patients with gout
   Thomas Bardin, Giovambattista Desideri · 2013 · Current Medical Research and Opinion
6. Rational use of recommendations for urate-lowering therapy: clinical examples
   М. С. Елисеев, Olga V. Zhelyabina · 2022 · Modern Rheumatology Journal
7. Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout
   Bishoy Kamel, Ahmad Y. Abuhelwa, David J. R. Foster, Janna K. Duong, Garry G. Graham, Kenneth M. Williams, Kevin D. Pile, Richard Osborne Day · 2022 · British Journal of Clinical Pharmacology
8. A Drug–Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia
   Chenjing Wang, Qing Yu, Xin Jiang, Yujie Deng, Feifei Sun, Xin Li, Ye Tao, Pingping Lin, Yaping Ma, Yuxian Zhu et al. · 2022 · The Journal of Clinical Pharmacology
9. Urate‐lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink
   Steven John Kiddle, Karolina Andersson Sundell, Shira Perl, STEPHEN T. NOLAN, Magnus K. Bjursell · 2024 · Clinical Cardiology
10. Analysis of Gout Remission Definitions in a Randomized Controlled Trial of Colchicine Prophylaxis for People With Gout Initiating Allopurinol
    Adwoa Dansoa Tabi‐Amponsah, Lisa K. Stamp, Anne M. Horne, Jill M. Drake, Sarah Stewart, Greg D. Gamble, Keith J. Petrie, Nicola Dalbeth · 2024 · The Journal of Rheumatology
11. Kristallinduzierte Inflammasomaktivierung: Gicht und Pseudogicht
    Maria Winzer, Anne Kathrin Tausche, Martin Aringer · 2009 · Zeitschrift für Rheumatologie
12. Les traitements hypo-uricémiants disponibles dans la goutte
    Pascal Richette · 2012 · Annales Pharmaceutiques Françaises
13. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective
    Lee J. Smolen, James C. Gahn, Ghaith Mitri, Aki Shiozawa · 2016 · Clinical Therapeutics
14. Asymptomatic Hyperuricemia
    Tuhina Neogi · 2012 · Elsevier eBooks
15. Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout
    Daniel Hill‐McManus, Scott F. Marshall, Elena Soto, Dyfrig Arwyn Hughes · 2019 · Clinical Pharmacology & Therapeutics
16. Development and Pilot Testing of MyGoutCare
    Puja P. Khanna, Veronica J. Berrocal, Larry C. An, Dinesh Khanna · 2019 · JCR Journal of Clinical Rheumatology
17. Penatalaksanaan Hiperurisemia Pada Penyakit Ginjal Kronik (CKD)
    Haidar Alatas · 2021 · Herb-Medicine Journal Terbitan Berkala Ilmiah Herbal Kedokteran dan Kesehatan
18. Anti-gout Medications and Risk of Cardiovascular Disease: A Nested Case-Control Study
    Tsung-Ju Chuang, Yu‐Hsun Wang, James Cheng‐Chung Wei, Chih‐Jung Yeh · 2021 · Frontiers in Medicine
19. Gout, hyperuricemia and chronic kidney disease: New treatment possibilities
    Paweł Kochman, Tomasz P. Stompór · 2016 · Polish Annals of Medicine
20. Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience
    Narisa Sulaiman, Ahmad Zaidi Othman, Nor Shuhaila Shahril, Anna Misyail Abdul Rashid, Mohamad Syafeeq Faeez Md Noh · 2017 · SAGE Open Medical Case Reports
21. Are participants in gout medication registration clinical trials representative of people with gout in the general population?
    Jendy Liu, Greg D. Gamble, Nicola Dalbeth · 2025 · Seminars in Arthritis and Rheumatism
22. Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies
    Kenneth G. Saag, Nicola Dalbeth, Chi‐yuan Hsu, Chang‐Fu Kuo, George Nuki, Fernando Pérez-Ruiz, William B. White, Ali Hariri, Yunjung Lee, Younghwan Jang et al. · 2025 · Contemporary Clinical Trials
23. Effects of sodium-glucose cotransporter-2 inhibitors on serum urate levels and gout in patients with and without type 2 diabetes: a systematic review and network meta-analysis
    Qiaozhi Hu, Shiwen Yang, Bofei Zhang, Na Su · 2025 · International Journal of Clinical Pharmacy
24. Differentialdiagnostik und Therapie der Gicht
    Monika A Reuss-Borst · 2009 · Medizinische Klinik - Intensivmedizin und Notfallmedizin
25. Goutte : mise en place et suivi du traitement hypo-uricémiant
    Pascal Richette · 2011 · Revue du Rhumatisme
26. How Would You Manage This Patient With Gout?
    Risa Beth Burns, Christopher C. Smith, Robert H. Shmerling, Anjala V. Tess · 2018 · Annals of Internal Medicine
27. Effect of uric acid-lowering therapy on renal function in patients with chronic kidney disease: a systematic review and meta-analysis
    Yukio Maruyama, Takanori Kumagai, Naoki Sugano, Shigetaka Yoshida, Kimiyoshi Ichida, Shunya Uchida · 2021 · Renal Replacement Therapy
28. Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia
    Roba Ghossan, Ouidade Aitisha Tabesh, Fouad Fayad, Pascal Richette, Thomas Bardin · 2023 · JCR Journal of Clinical Rheumatology
29. Gicht
    Vanessa Bartsch, Kathrin Standfest, Axel J. Hueber · 2025 · Zeitschrift für Gerontologie und Geriatrie
30. Review of Hyperuricaemia and Hypertension: A Target for Treatment
    Claudine G. Jennings · 2013 · Journal of Hypertension Open Access
31. Urate-Lowering Therapy
    Ted R. Mikuls · 2016 · Elsevier eBooks
32. [Hyperuricemia - more than gout : Impact on cardiovascular risk and renal insufficiency]
    Lorenz K. Sellin, Jan Thomas Kielstein, de Groot K · 2015 · Zeitschrift für Rheumatologie
33. Crystal arthropathies
    Spencer Ellis, G. Koduri · 2010 · Medicine
34. Easing the way to achieving target serum urate in people with gout: protocol for a non-inferiority randomised strategy trial using an allopurinol dosing model in Aotearoa/New Zealand (the Easy-Allo Study)
    Lisa K. Stamp, Leanne Te Karu, Susan Reid, Daniel F. B. Wright, Chris Miles Frampton, Vui Suli Tuitaupe, Nicola Dalbeth · 2024 · BMJ Open
35. Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study
    Jae‐Bum Jun, Hye‐Soon Lee, Sang-Hyon Kim, Seung‐Geun Lee, Doo‐Ho Lim, Jinhyun Kim, Yong‐Beom Park, Mie Jin Lim, Seung‐Jae Hong, Hyojin Choi et al. · 2025 · Arthritis Research & Therapy
36. Cost-effectiveness of nurse-led home monitoring of serum urate for gout patients starting with urate-lowering therapy in secondary care: a modeling study
    Jeffrey van der Ven, Marcel Flendrie, Fenne van Dijck, Maike H M Wientjes, Noortje van Herwaarden, Philip L. Riches, Bart J. F. van den Bemt, Lise M Verhoef · 2025 · Seminars in Arthritis and Rheumatism
37. Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males
    Jessica Hindi, Marc‐Olivier Pilon, Maxime Meloche, Grégoire Leclair, Essaïd Oussaïd, Isabelle St‐Jean, Martin Jutras, Marie‐Josée Gaulin, Ian Mongrain, David Busseuil et al. · 2023 · Clinical and Translational Science
38. Post-hoc analysis of two gout remission definitions in a two-year randomized controlled trial of nurse-led versus usual gout care
    Adwoa Dansoa Tabi‐Amponsah, Michael Doherty, Aliya Sarmanova, Weiya Zhang, Sarah Stewart, William John Taylor, Lisa K. Stamp, Nicola Dalbeth · 2024 · Seminars in Arthritis and Rheumatism
39. A systematic review and network meta-analysis of cardiovascular safety of benzbromarone compared to febuxostat and allopurinol in patients with gout
    Ting‐Syuan Lin, Yen-Liang Lin, Chiu-Hao Hsu, Song‐Chou Hsieh, Wen‐Yi Shau, Wei‐Shiung Yang, Chi‐Ling Chen · 2025 · Frontiers in Cardiovascular Medicine
40. The Role of Hyperuricemia in the Pathogenesis and Progressivity of Chronic Kidney Disease
    Gede Wira Mahadita, Ketut Suwitra · 2021 · Open Access Macedonian Journal of Medical Sciences
41. Promising actions of certain medicinal and dietary plants for the management of hyperuricemia as a natural remedy: A review
    Ananya Das, Prema Modak, Arghya Prosun Sarkar, Satyajit Halder, Bidduth Kumar Sarkar, Anita Rani Chowdhury, Sukalyan Kumar Kundu · 2020 · Asian Journal of Pharmacy and Pharmacology
42. Considerations for Choosing First-Line Urate-Lowering Treatment in Older Patients with Comorbid Conditions
    Eun Ha Kang · 2022 · Drugs & Aging
43. Colchicin – Phönix aus der Asche
    Raimund Lunzer, Georg Delle‐Karth, Markus Alexander Zeitlinger, Marlene Prager, Lena Pracher · 2025 · Wiener klinische Wochenschrift
44. Local oxygen concentration reversal from hyperoxia to hypoxia monitored by optical-resolution photoacoustic microscopy in inflammation-resolution process
    Yizhou Tan, Min Zhang, Zhifeng Wu, Jingqin Chen, Yaguang Ren, Chengbo Liu, Ying Gu · 2025 · Photoacoustics
45. Febuxostat for the treatment of hyperuricemia in patients with gout
    Victoria Kelly, Eswar Krishnan · 2011 · International Journal of Clinical Rheumatology
46. Febuxostat is superior to traditional urate-lowering agents in reducing the progression of kidney function in chronic kidney disease patients
    Shuo‐Chun Weng, Der‐Cherng Tarng, Yu‐Chi Chen, Ming‐Ju Wu, on behalf of the CKDBHPDH investigators · 2016 · Cogent Medicine
47. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout
    Ratchaya Lertnawapan, Kanon Jatuworapruk · 2020 · Clinical Rheumatology
48. Febuxostat and its major acyl glucuronide metabolite are potent inhibitors of organic anion transporter 3: Implications for drug‐drug interactions with rivaroxaban
    Lloyd Wei Tat Tang, Tino Woon Huai Cheong, Eric Chun Yong Chan · 2022 · Biopharmaceutics & Drug Disposition
49. Febuxostat dose requirement according to renal function in patients who achieve target serum urate levels: A retrospective cohort study
    Young-Eun Kim, Soo Min Ahn, Ji Seon Oh, Yong‐Gil Kim, Chang‐Keun Lee, Bin Yoo, Seokchan Hong · 2023 · Joint Bone Spine
50. Xanthine Oxidase Inhibitor Treatment of Hyperuricemia
    Nicola Dalbeth, Lisa K. Stamp · 2012 · Elsevier eBooks
51. Benefit Restrictions and Gout Treatment
    Sharon M. Wang, Gustavus A. Aranda, Sara Y. Gao, Bimal V. Patel · 2013 · Journal of Managed Care Pharmacy
52. Crystal Arthropathies: Recognizing and Treating “The Gouch”
    David M. Quillen · 2010 · Primary Care Clinics in Office Practice
53. Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective
    Robert W. Klein, Shaum Kabadi, Frank N. Cinfio, Christopher A. Bly, Douglas C.A. Taylor, Keith A. Szymanski · 2018 · Journal of Comparative Effectiveness Research
54. Comparisons of the Incidence and Critical Risk Factors of Metabolic Syndrome in Patients With a Rheumatic Disease or Gout
    HyunSoo Oh, JiSuk Park, YoungSub Yoon, WhaSook Seo · 2019 · Orthopaedic Nursing
55. International position paper on febuxostat
    Tim Jansen, Pascal Richette, Fernando Pérez-Ruiz, Anne‐Kathrin Tausche, Philip-André Guerne, Leonardo Punzi, Burkhard F. Leeb, В Г Барскова, Till Uhlig, José Bravo Pimentão et al. · 2010 · Clinical Rheumatology
56. Crystal arthropathies
    James A Stanway, Thiraupathy Marianayagam, Spencer Ellis · 2018 · Medicine
57. What is the Best Choice for Urate-lowering Therapy for Korean?
    Yun‐Hong Cheon, Jung Soo Song · 2020 · Journal of Rheumatic Diseases
58. Treat to target in gout by combining two modes of action
    Tim Jansen · 2014 · Lara D. Veeken
59. The efficacy and safety of different doses of febuxostat and allopurinol: A meta-analysis
    Feng Zhang, Yanyan Wang · 2025 · Joint Diseases and Related Surgery
60. Improvements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial
    Austin Barry, Bryant R. England, Harlan R Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb D. Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy et al. · 2025 · Arthritis Care & Research
61. Tiliroside Suppresses Uric Acid Production in Hepatocytes and Attenuates Purine-Induced Hyperuricemia in Male ICR Mice
    Shin-ichi Adachi, Shinji Kondo, Yusuke Sato, Fumiaki Yoshizawa, Kazumi Yagasaki · 2025 · Molecules
62. Hepatic Safety of Febuxostat and Allopurinol in Gout Patients: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Christiyanti Dewi, Falerina Puspita, Widya N. Insani, Rano Kurnia Sinuraya, Irma Melyani Puspitasari, Neily Zakiyah · 2025 · Therapeutics and Clinical Risk Management
63. Comprehensive Review on Febuxostat for Hyperuricemia with Gout: Insights from Current Practice and Clinical Trials
    Claudio Borghi, Federica Piani, Athanasios L. Manolis · 2025 · High Blood Pressure & Cardiovascular Prevention
64. Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis
    Seok Hui Kang, Bo‐Yeon Kim, Eun Jung Son, Gui Ok Kim, Jun Young Do · 2023 · American Journal of Nephrology
65. A patent review of xanthine oxidase inhibitors (2021–present)
    Chang Liu, Qing Mao, Bing Zhang, Xuefeng Fu, Tingjian Zhang, Shaojie Wang · 2024 · Expert Opinion on Therapeutic Patents
66. Novelties in gout
    Marija Radak-Perović, Mirjana Zlatković‐Švenda · 2013 · Srpski arhiv za celokupno lekarstvo
67. Anti-inflammatory and antipyretic analgesics and drugs used in gout
    Sebastian Straube · 2010 · Side effects of drugs annual
68. Solubility and Thermodynamic Properties of Febuxostat in Various (PEG 400 + Water) Mixtures
    Adel F. Alghaith, Wael Ali Mahdi, Nazrul Haq, Sultan Alshehri, Faiyaz Shakeel · 2022 · Materials
69. Characteristics of clinical manifestations of gout in the elderly people
    Larisa Rotaru, Liliana Groppa, Cătălin Codreanu, Larisa Spinei, Oleg Arnaut, Eugeniu Russu, Alesea Nistor, Lucia Dutca, Cristina Ana Maria Pamfil, Cornelia Cornea · 2022 · Romanian Journal of Rheumatology
70. The dose of febuxostat required to achieve the target level of uric acid in patients with normal and impaired renal function
    М. С. Елисеев, M. N. Chikina, Olga V. Zheliabina, Yа. I. Kuzmina · 2025 · Modern Rheumatology Journal
71. Comparison of Efficacy and Safety of Febuxostat in Gout Patients with Chronic Kidney Disease Stage 3 and Stage 4/5
    Eeunyoung Ahn, Sunggun Lee, Hanna Lee, Seung‐Geun Lee, Min Wook So · 2019 · Journal of Rheumatic Diseases
72. Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review.
    Aziz Rezapour, Saeide Alidoost, Asra Asgharzadeh, Zeynab Farhadi, Najme Khodadadi, Roghayeh Mohammadi Bakhsh, Razieh Sepehrian, Morteza Salemi, Masood Taheri Mirghaed, Masoud Behzadifar et al. · 2020 · PubMed Central
73. The Urate-lowering Efficacy and Safety of Febuxostat in Korean Patients with Gout
    Sung Hwan Park, Yeong Wook Song, Won Park, Eun Mi Koh, Bin Yoo, Soo Kon Lee, Dae‐Hyun Yoo, Yun Jong Lee, Hyun Ah Kim, Hyo Jin Choi et al. · 2013 · Journal of Rheumatic Diseases
74. Canakinumab (an interleukin 1β inhibitor) is a breakthrough in the possibilities of anti-inflammatory therapy for gout
    М. С. Елисеев, В Г Барскова, Evgeny Lvovich Nasonov · 2013 · Rheumatology Science and Practice
75. Gout: thoughts about a treat-to-target programme.
    Jürgen Braun, Josef S Smolen · 2012 · PubMed
76. [A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient].
    Yi Sun, Liang Li, Tianyan Zhou, Wei Lu · 2014 · PubMed
77. Metabolic risks of hyperuricemia
    Долгова Лидия Николаевна, И. Г. Красивина, Долгов Николай Владимирович, D. G. Lugovkina · 2019 · Meditsinskiy sovet = Medical Council
78. Hyperuricemia as the Factor of Kidney Damage and the Target of Therapy
    M S Yeliseyev · 2020 · Effective Pharmacotherapy
79. Treatment of Gout with Reduced Kidney Function
    A. M. Novikova, M S Yeliseyev · 2020 · Effective Pharmacotherapy
80. Modern paradigm of treatment of hyperuricemia and gout in comorbid patients with the development of cardio-vascular pathology
    Mazurov Vi, Irina B. Belyaeva, М. С. Петрова, R. A. Bashkinov · 2020 · Meditsinskiy sovet = Medical Council
81. Crystal arthropathies
    Thiraupathy Marianayagam, Gouri Koduri, Spencer Ellis · 2014 · Medicine
82. Neue Arzneimittel 2010
    Uwe Fricke, U. Schwabe · 2011 · Springer eBooks
83. Population Pharmacodynamic Analysis of Uric Acid–Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals
    Shota Muraki, Kuniaki Moriki, Saki Shigematsu, Masato Fukae, Makoto Kakara, Daiki Yamashita, Takeshi Hirota, Hiroshi Takane, Miki Shimada, Masaaki Hirakawa et al. · 2017 · The Journal of Clinical Pharmacology
84. Cardiovascular Safety of Febuxostat Versus Allopurinol in the Real World: Old Reliable Comes Out on Top
    Rekha Mankad · 2019 · Mayo Clinic Proceedings
85. Evaluating the drug-drug interactions of SHR4640 on repaglinide and midazolam in healthy subjects
    Yuanzhi Cheng, Xiaotong Hu, Zejun Pei, Zhe Zhang, Hongda Lin, Sheng Feng, Zhenyan Gao, Yanlin Ma, Zhihai Cao, Qian Zhang et al. · 2024 · Expert Opinion on Drug Metabolism & Toxicology
86. Efficacy of different dosages of common uric acid-lowering medications in gout patients: a network meta-analysis of randomized control trials
    Xiaojia Zheng, Cunxiang Xie, Jinying Fang, Zhenghui Huang, Jian Huang, Luming Zhao, Guancheng Ye, Hailong Wang · 2025 · Frontiers in Pharmacology
87. Effect modification by contextual factors of urate-lowering therapy on serum urate in people with gout: A systematic review with meta-regression analysis
    Ritch te Kampe, Sabrina Mai Nielsen, Ioana Hotea, Caroline MPG van Durme, Robin Christensen, Annelies E. R. C. H. Boonen · 2022 · Seminars in Arthritis and Rheumatism
88. The Rheumatology of Gout
    John S. Sundy · 2012 · Advances in Chronic Kidney Disease
89. New Drugs Approved in 2009
    Erin L. Sears, Sarah Brooks · 2010 · Baylor University Medical Center Proceedings
90. Advances and unmet needs in gout
    Brian T Fay, Ted R. Mikuls · 2010 · International Journal of Clinical Rheumatology
91. Management of gout: Primary care approach
    Olufemi Babatunde Omole, Gboyega Adebola Ogunbanjo · 2009 · South African Family Practice
92. Pegloticase: a new biologic for treating advanced gout
    Herbert S. B. Baraf, Alan K. Matsumoto · 2012 · International Journal of Clinical Rheumatology
93. Recent Progress in the Management of Gouty Arthritis and Hyperuricemia
    Won Park · 2011 · The Korean Journal of Internal Medicine
94. Comparative Efficacy and Safety of Febuxostat and Allopurinol in the Treatment of Hyperuricemia: A Bayesian Network Meta-analysis
    Gwan Gyu Song, Young Ho Lee · 2015 · Journal of Rheumatic Diseases
95. Inflammasom und Gicht
    Martin Aringer, Christian Michael Hedrich, Anne Kathrin Tausche · 2016 · Zeitschrift für Rheumatologie
96. Hyperuricaemia and gouty arthropathy: diagnosis and treatment
    Radka Svobodová · 2016 · Interní medicína pro praxi
97. FEBUXOSTAT FOR TREATMENT OF CHRONIC HYPERURICEMIA IN GOUT PATIENTS
    М. С. Петрова, Mazurov Vi, Oksana V. Inamova · 2017 · Meditsinskiy sovet = Medical Council
98. Uric Acid in Chronic Kidney Disease: A Clinical Appraisal
    Andrea Galassi, Maria Enrica Giovenzana, Federico Prolo, Antonio Bellasi, Mario Gennaro Cozzolino · 2016 · EMJ Nephrology
99. Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor
    Xiaotong Hu, Hongda Lin, Yan Huang, Pingsheng Xu, Bin Xu, Haibin Yu, Meixia Wang, Sheng Feng, Yijing Li, Kai Shen · 2024 · The Journal of Clinical Pharmacology
100. Case study: A case of debilitating gout in the 1st metatarsophalangeal joint
     Natalie Tanner, Ross Diaper, Mathew King, Stuart A. Metcalfe · 2014 · The Foot